{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:46Z","timestamp":1793814166824,"version":"4.6.1"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178397"],"award-info":[{"award-number":["R01CA178397"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA254354"],"award-info":[{"award-number":["R01CA254354"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA257602-01"],"award-info":[{"award-number":["R01CA257602-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100825","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T04:55:17Z","timestamp":1616043317000},"page":"100825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":195,"special_numbering":"C","title":["Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions"],"prefix":"10.1016","volume":"49","author":[{"given":"Afaf E.G.","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0010","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer."},{"issue":"Suppl","key":"10.1016\/j.blre.2021.100825_bb0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1269\/jrr.32.SUPPLEMENT_162","article-title":"Atomic bomb and leukemia","volume":"32","author":"Ichimaru","year":"1991","journal-title":"J Radiat Res"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0020","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2307\/3580328","article-title":"Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis","volume":"152","author":"Little","year":"1999","journal-title":"Radiat Res"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2021.100825_bb0025","first-page":"20","article-title":"Neoplastic diseases induced by chronic alpha-irradiation-- epidemiological, biophysical and clinical results of the German Thorotrast Study","volume":"32","author":"Van Kaick","year":"1991","journal-title":"JRadiatResTokyo."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0030","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0035","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u201cde novo\u201d resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"Aceves-Luquero","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O\u2019Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"10.1016\/j.blre.2021.100825_bb0050","doi-asserted-by":"crossref","first-page":"15174","DOI":"10.1073\/pnas.93.26.15174","article-title":"Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport","volume":"93","author":"Lewis","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4952","key":"10.1016\/j.blre.2021.100825_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2183353","article-title":"Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity","volume":"248","author":"Kipreos","year":"1990","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(94)90240-2","article-title":"The nuclear tyrosine kinase c-Abl negatively regulates cell growth","volume":"77","author":"Sawyers","year":"1994","journal-title":"Cell."},{"issue":"6632","key":"10.1016\/j.blre.2021.100825_bb0065","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/387516a0","article-title":"Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation","volume":"387","author":"Baskaran","year":"1997","journal-title":"Nature."},{"issue":"38","key":"10.1016\/j.blre.2021.100825_bb0070","doi-asserted-by":"crossref","first-page":"23485","DOI":"10.1074\/jbc.272.38.23485","article-title":"Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response","volume":"272","author":"Yuan","year":"1997","journal-title":"J Biol Chem"},{"issue":"6626","key":"10.1016\/j.blre.2021.100825_bb0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/386732a0","article-title":"Functional interaction between DNA-PK and c-Abl in response to DNA damage","volume":"386","author":"Kharbanda","year":"1997","journal-title":"Nature."},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0080","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1074\/jbc.273.7.3799","article-title":"Regulation of Rad51 function by c-Abl in response to DNA damage","volume":"273","author":"Yuan","year":"1998","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.blre.2021.100825_bb0085","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.onc.1201698","article-title":"Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation","volume":"16","author":"Yuan","year":"1998","journal-title":"Oncogene."},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. writing committee for the collaborative CML prognostic factors project group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","article-title":"The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms","volume":"184","author":"Vardiman","year":"2010","journal-title":"Chem-Biol Inter"},{"issue":"3\u20134","key":"10.1016\/j.blre.2021.100825_bb0100","first-page":"295","article-title":"Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patients","volume":"36","author":"Thiele","year":"2000","journal-title":"LeukLymphoma."},{"issue":"26","key":"10.1016\/j.blre.2021.100825_bb0105","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0115","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0120","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0130","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0135","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2007-02-074252","article-title":"Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia","volume":"110","author":"Kreil","year":"2007","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0140","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0145","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0150","first-page":"208","article-title":"P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?","volume":"8","author":"Melo","year":"1994","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0155","first-page":"186","article-title":"An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders","volume":"8","author":"Cross","year":"1994","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0160","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/leu.2015.196","article-title":"beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0165","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood.V88.6.2236.bloodjournal8862236","article-title":"A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia","volume":"88","author":"Hochhaus","year":"1996","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0170","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.leu.2403604","article-title":"e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?","volume":"19","author":"Demehri","year":"2005","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0175","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2002-03-0930","article-title":"CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall","volume":"100","author":"Al Ali","year":"2002","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo","year":"1993","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0185","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V99.12.4547","article-title":"Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability","volume":"99","author":"Huntly","year":"2002","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2021.100825_bb0190","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100825_bb0195","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100825_bb0200","doi-asserted-by":"crossref","unstructured":"Shanmuganathan N, Wadham C, Shahrin NH, Thomson D, Feng J, Saunders VA, et al. Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. Blood. 2020;136(Supplement 1):46-7.","DOI":"10.1182\/blood-2020-136962"},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0205","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2021.100825_bb0210","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"NEnglJMed."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0215","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2021.100825_bb0225","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic Myeloid Leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1988.6.1.180","article-title":"Definition of the accelerated phase of chronic myelogenous leukemia","volume":"6","author":"Kantarjian","year":"1988","journal-title":"J ClinOncol"},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0235","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0240","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2021.100825_bb0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0250","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0255","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.blre.2021.100825_bb0260","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood."},{"issue":"15","key":"10.1016\/j.blre.2021.100825_bb0265","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"NEnglJMed."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0270","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0275","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica."},{"issue":"14","key":"10.1016\/j.blre.2021.100825_bb0280","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"NEnglJMed."},{"issue":"14","key":"10.1016\/j.blre.2021.100825_bb0285","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"NEnglJMed."},{"issue":"2 Suppl 3","key":"10.1016\/j.blre.2021.100825_bb0290","first-page":"26","article-title":"Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"40","author":"O\u2019Brien","year":"2003","journal-title":"SeminHematol."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0295","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"long-term outcomes of imatinib treatment for chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0300","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial","volume":"94","author":"Guilhot","year":"2009","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2021.100825_bb0310","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","article-title":"Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party","volume":"113","author":"Castagnetti","year":"2009","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0315","first-page":"1634","article-title":"Tolerability-Adapted Imatinib 800 mg\/d Versus 400 mg\/d Versus 400 mg\/d Plus Interferon-{alpha} in Newly Diagnosed Chronic Myeloid Leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"JClinOncol."},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0320","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia."},{"issue":"26","key":"10.1016\/j.blre.2021.100825_bb0325","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"NEnglJMed."},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0330","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0335","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0340","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0345","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2021.100825_bb0350","first-page":"3204","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"JClinOncol."},{"issue":"25","key":"10.1016\/j.blre.2021.100825_bb0355","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0360","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2021.100825_bb0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0370","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0375","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le","year":"2008","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0380","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0385","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia."},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0390","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"NEnglJMed."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0395","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia."},{"issue":"35","key":"10.1016\/j.blre.2021.100825_bb0400","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2021.100825_bb0405","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0410","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"28","key":"10.1016\/j.blre.2021.100825_bb0420","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic Myeloid Leukemia: Results from the randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0430","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0435","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.blre.2021.100825_bb0440","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V116.21.210.210","article-title":"A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic Myelogenous Leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2021.100825_bb0445","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0450","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.blre.2021.100825_bb0455","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100825_bb0460","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-133922","article-title":"Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic Myeloid Leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): Analyses based on PACE and optic","volume":"136","author":"Kantarjian","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0465","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia."},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0470","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMp2027580","article-title":"Broken promises - how medicare part D has failed to deliver savings to older adults","volume":"383","author":"Dusetzina","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2021.100825_bb0475","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0480","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","article-title":"The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia","volume":"60","author":"Lasica","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0485","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0490","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood."},{"issue":"35","key":"10.1016\/j.blre.2021.100825_bb0495","first-page":"6041","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"JClinOncol."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0500","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0505","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.leukres.2011.10.016","article-title":"Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials","volume":"36","author":"Zhang","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0510","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0515","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0520","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0525","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cncr.29240","article-title":"Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0530","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0535","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0540","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic Myeloid Leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0555","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0560","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0565","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0570","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0575","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0580","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0585","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0590","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Schutz","year":"2017","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0595","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.blre.2021.100825_bb0600","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5531","key":"10.1016\/j.blre.2021.100825_bb0605","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.blre.2021.100825_bb0610","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0615","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0625","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood."},{"issue":"36","key":"10.1016\/j.blre.2021.100825_bb0630","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0640","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0645","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100825_bb0650","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0655","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0660","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161470","article-title":"ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines","volume":"11","author":"Eadie","year":"2016","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.blre.2021.100825_bb0670","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2021.100825_bb0675","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.blre.2021.100825_bb0680","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100825_bb0685","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0690","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2021.100825_bb0695","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"issue":"7647","key":"10.1016\/j.blre.2021.100825_bb0700","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature."},{"issue":"14","key":"10.1016\/j.blre.2021.100825_bb0705","first-page":"1379","article-title":"Asciminib in Relapsed Chronic Myeloid Leukemia. Reply","volume":"382","author":"Mauro","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0710","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic Myeloid Leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100825_bb0715","author":"Hochhaus","year":"2020"},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0720","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0725","first-page":"424","article-title":"The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage","volume":"79","author":"Elmaagacli","year":"2000","journal-title":"AnnHematol."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0730","first-page":"48","article-title":"BCR-ABL suppresses C\/EBPalpha expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"NatGenet."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0735","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","article-title":"miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts","volume":"140","author":"Eiring","year":"2010","journal-title":"Cell."},{"issue":"3","key":"10.1016\/j.blre.2021.100825_bb0740","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/bloodadvances.2018024422","article-title":"RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs","volume":"3","author":"Gerritsen","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0745","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0750","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2005-08-3181","article-title":"Inducible activation of CEBPB, a gene negatively regulated by BCR\/ABL, inhibits proliferation and promotes differentiation of BCR\/ABL-expressing cells","volume":"107","author":"Guerzoni","year":"2006","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2021.100825_bb0755","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.onc.1207143","article-title":"Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1\/MDS1\/EVI1 with BCR\/ABL in the induction of acute myelogenous leukemia in mice","volume":"23","author":"Cuenco","year":"2004","journal-title":"Oncogene."},{"key":"10.1016\/j.blre.2021.100825_bb0760","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-2407-8-193","article-title":"EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22)","volume":"8","author":"De Weer","year":"2008","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0765","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.blre.2021.100825_bb0770","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2021.100825_bb0775","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0780","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41375-020-0751-y","article-title":"Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia","volume":"34","author":"Thomson","year":"2020","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0785","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2019-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.blre.2021.100825_bb0790","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0795","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0800","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/10428194.2017.1397666","article-title":"Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia","volume":"59","author":"Ruggiu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0805","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia."},{"issue":"17","key":"10.1016\/j.blre.2021.100825_bb0810","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation."},{"issue":"20","key":"10.1016\/j.blre.2021.100825_bb0815","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic Myeloid Leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0820","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0830","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer."},{"issue":"13","key":"10.1016\/j.blre.2021.100825_bb0835","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.blre.2021.100825_bb0840","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2021.100825_bb0845","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.blre.2021.100825_bb0850","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.blre.2021.100825_bb0855","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2021.100825_bb0860","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","article-title":"A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease","volume":"34","author":"Horne","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2021.100825_bb0865","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.blre.2021.100825_bb0870","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1038\/s41375-020-01037-9","article-title":"Declaration of Bcr-Abl1 independence","volume":"34","author":"Zhao","year":"2020","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.blre.2021.100825_bb0875","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica."},{"issue":"22","key":"10.1016\/j.blre.2021.100825_bb0880","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V128.22.1122.1122","article-title":"Enhanced natural killer and cytotoxic T lymphocyte responses, with decreased monocytic myeloid derived suppressor cells may promote treatment free remission in chronic myeloid leukaemia patients following tyrosine kinase inhibitor cessation","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2021.100825_bb0885","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica."},{"issue":"252","key":"10.1016\/j.blre.2021.100825_bb0890","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2100031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2100031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:46Z","timestamp":1759436746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2100031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":178,"alternative-id":["S0268960X2100031X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100825","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100825"}}